secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001356576-24-000018
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus receives FDA Complete Response Letter for SPN-830 (apomorphine infusion device)
--------------------------------------------------------------------------------

- FDA issued CRL stating NDA for SPN-830 (apomorphine infusion) not ready for approval.
- Two areas: product quality (additional data submitted but not reviewed) and device master file from manufacturer.
- No clinical safety or efficacy issues identified as barriers to approval.
- FDA completed successful preapproval inspection of device manufacturer's facility in Feb 2024.
- Supernus plans to work with device manufacturer and FDA to resubmit NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000018/0001356576-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000018/supn-20240408.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer